After corneal transplantation, rejection may result in failure of the graft and another transplant may be required. The rate of corneal transparency following corneal transplantation is 80–90% for the initial transplant and 40% for re-transplantation, indicating that regular corneal transplantation is unlikely to achieve good results in patients with a history of multiple graft failures.
As a treatment option for these patients, artificial corneas are currently being used. The Boston Keratoprosthesis (KPro) type I, developed in 1990 at the Massachusetts Eye and Ear Infirmary in the United States, is used to replace only the center of the corneal graft with a small plastic lens (polymethyl metacrylate, PMMA). Therefore, the advantage of the Boston KPro is that it reduces the frequency of rejections, and in addition, with appropriate postoperative care, it is possible to achieve good, stable, long-term recovery of visual acuity from the early postoperative period. It has already been used in over 6,000 patients worldwide, with reports demonstrating good long-term results. At our hospital as well, we have used it and achieved good postoperative results in all patients, with no loss of the artificial cornea or occurrence of side effects such as severe infection, even after three or more years of postoperative follow-up.
The disadvantages of Boston KPro include its relatively high cost and the need for a human corneal graft. However, we are actively introducing this technique at our hospital using internationally sourced corneas for those patients for whom it is indicated.
Our hospital is a specialist ophthalmology hospital that attracts patients from all over the country because it is well-known nationally for its cutting-edge equipment and highly-skilled staff, which, despite its nature as a private hospital, rivals those that can be found in university hospitals. In addition to corneal transplantation, it also offers world-class diagnosis and treatment of cataracts. In particular, we use the world’s most advanced testing device, developed in collaboration with the manufacturer, in selecting the intraocular lens. In addition to our doctors, the technicians and the analytical equipment we use are all high-level, demonstrating the hospital’s all-round strength.
The hospital also incorporates a level P1/P2 Biosafety Research Laboratory and Cornea Center. Here, patients’ own blood is used to produce both fibronectin and serum eyedrops, which are effective treatments for corneal disease. Research is also carried out in areas including the culture of infective pathogens and their simplified identification, as well as the long-term durability evaluation of intraocular lenses. Our hospital is thus actively engaged not only in everyday clinical treatment, but in clinical research that will be genuinely beneficial to future generations of patients as well.
Dr. Kazunori Miyata
Chairman of the Board of Directors/Hospital Director
Even if you have previously undergone corneal transplantation with poor results due to rejection and been told that further transplants are unlikely to be successful, please consult us. Our testing, surgery, and postoperative care may enable the restoration of your visual function. We also offer special outpatient services for other eye disorders, staffed by top-ranked specialists from all over Japan, which ensures high standards in diagnosis and treatment. The eye may be a small organ, but it is vital for everyday life. Our unwavering objective is to offer the highest level, most advanced testing and treatment possible in order to restore smiles to the faces of patients with eye disorders.
You are required to make a preliminary visit to Japan to undergo various tests over a one- or two-day period in order to determine your eligibility, specifically to confirm sufficient tear production and remaining visual function. To facilitate the determination of eligibility, we recommend that you undergo examinations in your home country to confirm that general anesthesia is safe for you, as it may be necessary. After you have been approved for treatment, a one-month waiting period is required before surgery due to the need to obtain both the Boston KPro and the donor cornea.
|External View of Our Hospital||Structure of Boston KPro||After Transplantation of Boston KPro|
|Clinical Departments (Specialty Outpatient)
Myopia Correction Surgery (LASIK, PRK), Cataracts, Glaucoma Specialist Outpatient Clinics (Cataract, Glaucoma, Cornea, Refractive Correction, Keratoconus, Dry Eye, Uvea, Vitreoretinal, Strabismus/Amblyopia, Pediatric Ophthalmology, Neuro-ophthalmology, Plastic Surgery, Anesthesiology, Diabetes Medicine, Carotid Artery, Ocular Prostheses)
Cash, Credit Card (VISA, MasterCard, and JCB; only for myopia correction surgery)
6-3 Kurahara-cho, Miyakonojo-shi, Miyazaki 885-0051
|Approximately 8 minutes on foot
from the JR Nishi-Miyakonojo Station
|Approximately 60 minutes
from Miyazaki Airport by car